{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:26:23Z","timestamp":1765887983752,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.amjsurg.2018.03.020","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T18:29:21Z","timestamp":1521397761000},"page":"931-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pre-surgical chemotherapy for breast cancer may be associated with improved outcomes"],"prefix":"10.1016","volume":"215","author":[{"given":"Madeline","family":"Cook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.amjsurg.2018.03.020_bib1","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A\u00a0multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.amjsurg.2018.03.020_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.amjsurg.2018.03.020_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18","volume":"2001","author":"Wolmark","year":"2001","journal-title":"JNCI Monographs"},{"issue":"3","key":"10.1016\/j.amjsurg.2018.03.020_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"JNCI J Natl Canc Inst"},{"issue":"28","key":"10.1016\/j.amjsurg.2018.03.020_bib5","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.amjsurg.2018.03.020_bib6","doi-asserted-by":"crossref","DOI":"10.3747\/co.v15i6.242","article-title":"Residual cancer burden in locally advanced breast cancer: a superior tool","volume":"15","author":"Nahleh","year":"2008","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.amjsurg.2018.03.020_bib7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.amjsurg.2018.03.020_bib8","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.amjsurg.2018.03.020_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","article-title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","volume":"8","author":"Krag","year":"2007","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.amjsurg.2018.03.020_bib10","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.amjsurg.2018.03.020_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-013-0364-y","article-title":"Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used","volume":"16","author":"Mamounas","year":"2014","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.amjsurg.2018.03.020_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection","volume":"102","author":"Ashikaga","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"issue":"11","key":"10.1016\/j.amjsurg.2018.03.020_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archsurg.137.11.1253","article-title":"Lymphedema and quality of life in survivors of early-stage breast cancer","volume":"137","author":"Beaulac","year":"2002","journal-title":"Arch Surg"},{"issue":"12","key":"10.1016\/j.amjsurg.2018.03.020_bib14","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1245\/s10434-017-6016-y","article-title":"The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype","volume":"24","author":"Pilewskie","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.amjsurg.2018.03.020_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer","volume":"110","author":"Semiglazov","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.amjsurg.2018.03.020_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-008-9915-6","article-title":"Increase in response rate by prolonged treatment with neoadjuvant letrozole","volume":"113","author":"Dixon","year":"2008","journal-title":"Breast Canc Res Treat"},{"issue":"22","key":"10.1016\/j.amjsurg.2018.03.020_bib17","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961017315374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961017315374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:13:03Z","timestamp":1757700783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961017315374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0002961017315374"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2018.03.020","relation":{},"ISSN":["0002-9610"],"issn-type":[{"type":"print","value":"0002-9610"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-surgical chemotherapy for breast cancer may be associated with improved outcomes","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2018.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}